{"id":"cggv:a8f8af21-a5dc-41aa-9bd3-b38c3a98d55cv1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:a8f8af21-a5dc-41aa-9bd3-b38c3a98d55c_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10135","date":"2024-07-23T19:35:05.543Z","role":"Publisher"},{"id":"cggv:a8f8af21-a5dc-41aa-9bd3-b38c3a98d55c_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10135","date":"2024-07-03T16:00:00.000Z","role":"Approver"}],"curationReasons":{"id":"cg:NewCuration"},"evidence":[{"id":"cggv:a8f8af21-a5dc-41aa-9bd3-b38c3a98d55c_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:a8f8af21-a5dc-41aa-9bd3-b38c3a98d55c_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":11.5},{"id":"cggv:67f80527-eeb3-4099-a572-84081bd34a89_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:67f80527-eeb3-4099-a572-84081bd34a89","type":"Proband","allele":{"id":"cggv:e88bbb68-af12-4e29-9e41-08c79bd621f5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001244710.2(GFPT1):c.1096G>T (p.Asp366Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347126229"}},"detectionMethod":"All genes involved in CMS were excluded by direct sequencing or by haplotype analysis: CHAT, CHRNA1, CHRNB1, CHRND, CHRNE, COLQ, DOK7, RAPSN, MUSK, SCN4A, LAMB2, AGRN, CNTN1, ACHE","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"Data provided in aggregate: limb-girldle weakness, RNS decrement, myopathic EMG changes, effective AChE inhibitor therapy, age of onset in 1st decade, tubular aggregates, elevated CK, distal limb weakness, facial weakness, permanent muscle weakness, neck muscle weakness, delayed motor milestones, ptosis, respiratory weakness, ophthalmoparesis, bulbar weakness.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:4af11c8b-b704-4324-b124-5895c7e4f8ff_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:e88bbb68-af12-4e29-9e41-08c79bd621f5"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/21310273","type":"dc:BibliographicResource","dc:abstract":"Neuromuscular junctions (NMJs) are synapses that transmit impulses from motor neurons to skeletal muscle fibers leading to muscle contraction. Study of hereditary disorders of neuromuscular transmission, termed congenital myasthenic syndromes (CMS), has helped elucidate fundamental processes influencing development and function of the nerve-muscle synapse. Using genetic linkage, we find 18 different biallelic mutations in the gene encoding glutamine-fructose-6-phosphate transaminase 1 (GFPT1) in 13 unrelated families with an autosomal recessive CMS. Consistent with these data, downregulation of the GFPT1 ortholog gfpt1 in zebrafish embryos altered muscle fiber morphology and impaired neuromuscular junction development. GFPT1 is the key enzyme of the hexosamine pathway yielding the amino sugar UDP-N-acetylglucosamine, an essential substrate for protein glycosylation. Our findings provide further impetus to study the glycobiology of NMJ and synapses in general.","dc:creator":"Senderek J","dc:date":"2011","dc:title":"Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect."}},"rdfs:label":"LGM1.4"},{"id":"cggv:4af11c8b-b704-4324-b124-5895c7e4f8ff","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:4af11c8b-b704-4324-b124-5895c7e4f8ff_variant_evidence_item"},{"id":"cggv:4af11c8b-b704-4324-b124-5895c7e4f8ff_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Enzymatic activity in HEK293 cells was mildly reduced (figure S6) to about 70% of wt."}],"strengthScore":0.25,"dc:description":"Activity was only mildly reduced in HEK293 cells."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:4bf425c6-a156-45ef-a0f2-97c47bbfdf53_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:4bf425c6-a156-45ef-a0f2-97c47bbfdf53","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":4,"allele":[{"id":"cggv:60f0c34e-fdfb-4967-85c0-2ee73f96883f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001244710.2(GFPT1):c.44C>T (p.Thr15Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1693995"}},{"id":"cggv:852d2b71-d7cc-467b-b157-91934439df2e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001244710.2(GFPT1):c.1_2del (p.Met1ValfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2576991603"}}],"detectionMethod":"WES performed for patients 3, 5, 6, and 8. Sanger sequencing for others.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Needle EMG studies revealed unstable small motor unit potentials","phenotypes":["obo:HP_0002460","obo:HP_0003325","obo:HP_0003403"],"previousTesting":true,"previousTestingDescription":"Negative test for anti-AChR antibodies. RAPSN, DOK7, and CHRNE variants ruled out in all patients. CHRNA1, CHRNB1, and CHNRD ruled out in patients 1-6 and 9-11. ","sex":"UnknownEthnicity","variant":[{"id":"cggv:66564719-80fc-4d13-995a-00d7db4c2bab_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:60f0c34e-fdfb-4967-85c0-2ee73f96883f"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23794683","type":"dc:BibliographicResource","dc:abstract":"To identify patients with GFPT1-related limb-girdle myasthenia and analyze phenotypic consequences of the mutations.","dc:creator":"Selcen D","dc:date":"2013","dc:title":"GFPT1-myasthenia: clinical, structural, and electrophysiologic heterogeneity."}},{"id":"cggv:62621eb3-4ec9-49ed-9d47-4b049175b43b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:852d2b71-d7cc-467b-b157-91934439df2e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23794683"}],"rdfs:label":"Selcen 2013 Patient 9"},{"id":"cggv:66564719-80fc-4d13-995a-00d7db4c2bab","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:66564719-80fc-4d13-995a-00d7db4c2bab_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:62621eb3-4ec9-49ed-9d47-4b049175b43b","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:62621eb3-4ec9-49ed-9d47-4b049175b43b_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:b7edff4b-d290-4faf-b431-71b43f93d8a4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:b7edff4b-d290-4faf-b431-71b43f93d8a4","type":"Proband","allele":[{"id":"cggv:1dd92838-1431-4e2c-a26e-8683a8ce4499","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001244710.2(GFPT1):c.128A>T (p.Asp43Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347134919"}},{"id":"cggv:8443d305-84c9-41fc-bcc5-2cfea6a4008e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001244710.2(GFPT1):c.362T>C (p.Ile121Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1693902"}}],"detectionMethod":"All genes involved in CMS were excluded by direct sequencing or by haplotype analysis: CHAT, CHRNA1, CHRNB1, CHRND, CHRNE, COLQ, DOK7, RAPSN, MUSK, SCN4A, LAMB2, AGRN, CNTN1, ACHE","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Data provided in aggregate: limb-girldle weakness, RNS decrement, myopathic EMG changes, effective AChE inhibitor therapy, age of onset in 1st decade, tubular aggregates, elevated CK, distal limb weakness, facial weakness, permanent muscle weakness, neck muscle weakness, delayed motor milestones, ptosis, respiratory weakness, ophthalmoparesis, bulbar weakness.","sex":"Male","variant":[{"id":"cggv:d62f73cf-4101-4c8c-8ce3-f398aefbd69d_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:1dd92838-1431-4e2c-a26e-8683a8ce4499"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21310273"},{"id":"cggv:f9b37f1f-eae7-4b6a-a1aa-d645400be412_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:8443d305-84c9-41fc-bcc5-2cfea6a4008e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21310273"}],"rdfs:label":"LGM6.4"},{"id":"cggv:f9b37f1f-eae7-4b6a-a1aa-d645400be412","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:f9b37f1f-eae7-4b6a-a1aa-d645400be412_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:d62f73cf-4101-4c8c-8ce3-f398aefbd69d","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:d62f73cf-4101-4c8c-8ce3-f398aefbd69d_variant_evidence_item"},{"id":"cggv:d62f73cf-4101-4c8c-8ce3-f398aefbd69d_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Enzyme activity in HEK293 cells was significantly reduced (~55% of wt)."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:104fb0df-181b-4f8d-a7fc-d5629f051858_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:104fb0df-181b-4f8d-a7fc-d5629f051858","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":8,"allele":[{"id":"cggv:fc995451-8fd0-44fe-b06c-f8fee6e60560","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001244710.2(GFPT1):c.*22C>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA204561"}},{"id":"cggv:9e47714d-f954-4ea4-a1d3-7332eb7eb02e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001244710.2(GFPT1):c.1688G>C (p.Arg563Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347422559"}}],"detectionMethod":"WES performed for patients 3, 5, 6, and 8. Sanger sequencing for others.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Needle EMG studies revealed unstable small motor unit potentials","phenotypes":["obo:HP_0002460","obo:HP_0003325","obo:HP_0003403"],"previousTesting":true,"previousTestingDescription":"Negative test for anti-AChR antibodies. RAPSN, DOK7, and CHRNE variants ruled out in all patients. CHRNA1, CHRNB1, and CHNRD ruled out in patients 1-6 and 9-11. ","sex":"Female","variant":[{"id":"cggv:ef784083-4ead-4358-87b5-5f2624537fdc_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:9e47714d-f954-4ea4-a1d3-7332eb7eb02e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23794683"},{"id":"cggv:faf5ee5b-267f-44f8-aa99-cc2ce5ca9f43_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fc995451-8fd0-44fe-b06c-f8fee6e60560"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23794683"}],"rdfs:label":"Selcen 2013 Patient 2"},{"id":"cggv:ef784083-4ead-4358-87b5-5f2624537fdc","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:ef784083-4ead-4358-87b5-5f2624537fdc_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:faf5ee5b-267f-44f8-aa99-cc2ce5ca9f43","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:faf5ee5b-267f-44f8-aa99-cc2ce5ca9f43_variant_evidence_item"},{"id":"cggv:faf5ee5b-267f-44f8-aa99-cc2ce5ca9f43_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"The variant leads to illegitimate binding of microRNA resulting in reduced protein expression. (PMID: 25765662)."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:09f6a407-ac2a-4e94-80d3-571fa218cd07_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:09f6a407-ac2a-4e94-80d3-571fa218cd07","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"allele":[{"id":"cggv:1ddfbeb0-01bf-460d-93ae-bf0375d2da6d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001244710.2(GFPT1):c.1754_1770dup (p.Gly591LeufsTer9)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2586969367"}},{"id":"cggv:fc995451-8fd0-44fe-b06c-f8fee6e60560"}],"detectionMethod":"WES performed for patients 3, 5, 6, and 8. Sanger sequencing for others.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Needle EMG studies revealed unstable small motor unit potentials","phenotypes":["obo:HP_0003325","obo:HP_0003403","obo:HP_0002460"],"previousTesting":true,"previousTestingDescription":"Negative test for anti-AChR antibodies. RAPSN, DOK7, and CHRNE variants ruled out in all patients. CHRNA1, CHRNB1, and CHNRD ruled out in patients 1-6 and 9-11. ","sex":"Male","variant":[{"id":"cggv:c1953906-565f-4465-857b-4ed2dc400bc2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:1ddfbeb0-01bf-460d-93ae-bf0375d2da6d"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23794683"},{"id":"cggv:0b40e20e-f6a3-4e8b-85f3-8e1c2c76c94a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fc995451-8fd0-44fe-b06c-f8fee6e60560"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23794683"}],"rdfs:label":"Selcen 2013 Patient 1"},{"id":"cggv:0b40e20e-f6a3-4e8b-85f3-8e1c2c76c94a","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:0b40e20e-f6a3-4e8b-85f3-8e1c2c76c94a_variant_evidence_item"},{"id":"cggv:0b40e20e-f6a3-4e8b-85f3-8e1c2c76c94a_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"The variant leads to illegitimate binding of microRNA resulting in reduced protein expression. (PMID: 25765662)."}],"strengthScore":0.5},{"id":"cggv:c1953906-565f-4465-857b-4ed2dc400bc2","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:c1953906-565f-4465-857b-4ed2dc400bc2_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:a8f8af21-a5dc-41aa-9bd3-b38c3a98d55c_seg_el","type":"EvidenceLine","specifiedBy":"GeneValiditySegregationEvidencCriteria","strengthScore":1},{"id":"cggv:449793b1-6665-4da6-bd6b-c15c0d082814_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:449793b1-6665-4da6-bd6b-c15c0d082814","type":"Proband","allele":{"id":"cggv:fc44d0c3-8605-44c0-b0f6-331288cebe46","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001244710.2(GFPT1):c.331C>T (p.Arg111Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA128605"}},"detectionMethod":"All genes involved in CMS were excluded by direct sequencing or by haplotype analysis: CHAT, CHRNA1, CHRNB1, CHRND, CHRNE, COLQ, DOK7, RAPSN, MUSK, SCN4A, LAMB2, AGRN, CNTN1, ACHE","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"Data provided in aggregate: limb-girldle weakness, RNS decrement, myopathic EMG changes, effective AChE inhibitor therapy, age of onset in 1st decade, tubular aggregates, elevated CK, distal limb weakness, facial weakness, permanent muscle weakness, neck muscle weakness, delayed motor milestones, ptosis, respiratory weakness, ophthalmoparesis, bulbar weakness.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:427492fc-2c5c-4fbb-a749-8c0404fbc7fa_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fc44d0c3-8605-44c0-b0f6-331288cebe46"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21310273"},"rdfs:label":"LGM3.3"},{"id":"cggv:427492fc-2c5c-4fbb-a749-8c0404fbc7fa","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:427492fc-2c5c-4fbb-a749-8c0404fbc7fa_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:5929efbc-660f-422e-8454-3fb113de651a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:5929efbc-660f-422e-8454-3fb113de651a","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"allele":[{"id":"cggv:c9858fbe-b1d6-439d-98ca-e0069d16ad23","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001244710.2(GFPT1):c.740-2A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347129004"}},{"id":"cggv:c23c3b1f-188f-414d-a367-ebcf6db917ef","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001244710.2(GFPT1):c.964C>T (p.Arg322del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1693737"}}],"detectionMethod":"WES performed for patients 3, 5, 6, and 8. Sanger sequencing for others.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Needle EMG studies revealed unstable small motor unit potentials","phenotypes":["obo:HP_0002460","obo:HP_0003403","obo:HP_0003325"],"previousTesting":true,"previousTestingDescription":"Negative test for anti-AChR antibodies. RAPSN, DOK7, and CHRNE variants ruled out in all patients. CHRNA1, CHRNB1, and CHNRD ruled out in patients 1-6 and 9-11. MUSK ruled out in patient 6.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"cggv:dde482eb-bb1f-4305-bedd-700504c40e34_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c9858fbe-b1d6-439d-98ca-e0069d16ad23"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23794683"},{"id":"cggv:c980eb8b-8b0b-4ad5-911e-dae672c28f45_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c23c3b1f-188f-414d-a367-ebcf6db917ef"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23794683"}],"rdfs:label":"Selcen 2013 Patient 6"},{"id":"cggv:dde482eb-bb1f-4305-bedd-700504c40e34","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:dde482eb-bb1f-4305-bedd-700504c40e34_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:c980eb8b-8b0b-4ad5-911e-dae672c28f45","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:c980eb8b-8b0b-4ad5-911e-dae672c28f45_variant_evidence_item"}],"strengthScore":1.5,"dc:description":"Note: The title of the variant is showing up as p.Arg322del but is actually p.Arg322Ter"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:751e2b70-932f-491e-8034-bdd1d10cc3d2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:751e2b70-932f-491e-8034-bdd1d10cc3d2","type":"Proband","allele":{"id":"cggv:ba6e7a2e-3ce5-4c52-b70b-58b466c685b0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001244710.2(GFPT1):c.719G>A (p.Trp240del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347129617"}},"detectionMethod":"All genes involved in CMS were excluded by direct sequencing or by haplotype analysis: CHAT, CHRNA1, CHRNB1, CHRND, CHRNE, COLQ, DOK7, RAPSN, MUSK, SCN4A, LAMB2, AGRN, CNTN1, ACHE","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"Data provided in aggregate: limb-girldle weakness, RNS decrement, myopathic EMG changes, effective AChE inhibitor therapy, age of onset in 1st decade, tubular aggregates, elevated CK, distal limb weakness, facial weakness, permanent muscle weakness, neck muscle weakness, delayed motor milestones, ptosis, respiratory weakness, ophthalmoparesis, bulbar weakness.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:2772aea6-97d8-496e-8cb6-bf54b40e9dcd_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:ba6e7a2e-3ce5-4c52-b70b-58b466c685b0"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21310273"},"rdfs:label":"LGM2.4"},{"id":"cggv:2772aea6-97d8-496e-8cb6-bf54b40e9dcd","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:2772aea6-97d8-496e-8cb6-bf54b40e9dcd_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:a8f8af21-a5dc-41aa-9bd3-b38c3a98d55c_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:a8f8af21-a5dc-41aa-9bd3-b38c3a98d55c_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:bc8bc02c-122c-4f85-aef1-4315a90afbb8","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:e3c71448-0048-4f90-831c-7e4645d9cb26","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"Subsequent cloning and sequencing revealed two GFAT1 mRNAs in both mouse and human skeletal muscles. The novel GFAT1 mRNA (GFAT1Alt [muscle selective variant of GFAT1]) is likely a splice variant. It is identical to GFAT1 except for a 48 or 54 bp insert in the mouse and human, respectively, at nucleotide position 686 of the coding sequence, resulting in a 16 or 18 amino acid insert at position 229 of the protein. GFAT1Alt is the predominant GFAT1 mRNA in mouse hindlimb muscle, is weakly expressed in the heart, and is undetectable in the brain, liver, kidney, lung, intestine, spleen, and 3T3-L1 adipocytes. In humans, it is strongly expressed in skeletal muscle but not in the brain.\n","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/11679416","type":"dc:BibliographicResource","dc:abstract":"Glutamine:fructose-6-phosphate amidotransferase(GFAT) is the rate-limiting enzyme of the hexosamine synthesis pathway. Products of this pathway have been implicated in insulin resistance and glucose toxicity. GFAT1 is ubiquitous, whereas GFAT2 is expressed mainly in the central nervous system. In the course of developing a competitive reverse transcriptase-polymerase chain reaction assay, we noted that GFAT1 cDNA from muscle but not from other tissues migrated as a doublet. Subsequent cloning and sequencing revealed two GFAT1 mRNAs in both mouse and human skeletal muscles. The novel GFAT1 mRNA (GFAT1Alt [muscle selective variant of GFAT1]) is likely a splice variant. It is identical to GFAT1 except for a 48 or 54 bp insert in the mouse and human, respectively, at nucleotide position 686 of the coding sequence, resulting in a 16 or 18 amino acid insert at position 229 of the protein. GFAT1Alt is the predominant GFAT1 mRNA in mouse hindlimb muscle, is weakly expressed in the heart, and is undetectable in the brain, liver, kidney, lung, intestine, spleen, and 3T3-L1 adipocytes. In humans, it is strongly expressed in skeletal muscle but not in the brain. GFAT1 and GFAT1Alt expressed by recombinant adenovirus infection in COS-7 cells displayed robust enzyme activity and kinetic differences. The apparent K(m) of GFAT1Alt for fructose-6-phosphate was approximately twofold higher than that of GFAT1, whereas K(i) for UDP-N-acetylglucosamine was approximately fivefold lower. Muscle insulin resistance is a hallmark and predictor of type 2 diabetes. Variations in the expression of GFAT isoforms in muscle may contribute to predisposition to insulin resistance.","dc:creator":"DeHaven JE","dc:date":"2001","dc:title":"A novel variant of glutamine: fructose-6-phosphate amidotransferase-1 (GFAT1) mRNA is selectively expressed in striated muscle."},"rdfs:label":"Skeletal muscle expression"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1,"dc:description":"In Senderek, 2011, GFPT1 expression was reduced in muscle biopsy of 4 patients."},{"id":"cggv:5bb5f66d-6def-4116-a70b-c117a1afe744","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:b2d6f6fe-c173-4fb6-9465-0bb15d534990","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"Summarized in this paper: \"GFPT1 catalyzes the transfer of an amino group from glutamine onto fructose-6-phosphate, yielding glucosamine-6-phosphate (GlcN-6-P) and glutamate. This transamidase reaction has been identified as the first and rate-limiting step of the hexosamine biosynthesis pathway, which is the obligatory source of essential amino sugars for the synthesis of glycoproteins, glycolipids, and proteoglycans (Figure S1, available online). As many key NMJ proteins are glycosylated, our data will pave the way for new studies on the functional integrity of the neuromuscular synapse.\"","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21310273","rdfs:label":"Biochemical function"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1,"dc:description":"Biochemical function consistent with disorder of glycosylation."}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"cggv:a8f8af21-a5dc-41aa-9bd3-b38c3a98d55c_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:c68ba2ce-f2d2-40db-897e-c6c1837276a3","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:2f307ff5-ad6e-4745-a004-9692f7e56a42","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Morpholino-mediated knockdown of gfpt1 in zebrafish embyros induced a neuromuscular phenotype, altered muscle histology, and delayed NMJ maturation. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21310273","rdfs:label":"Senderek 2011 Zebrafish"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"cggv:872b170a-2fdb-4441-a979-1021fc33081b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:d9e5aa5a-ad20-483f-ba49-57823ed51e69","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Gfpt1-muscle knockout mice display poor motor performance, muscle fatigue, reduced contractile properties of diaphragm muscles, histological changes in skeletal muscle, presynaptic and postynaptic remodeling, which are all consitent with congenital myasthenic syndrome characterized by fatiguable muscle weakness.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/29905857","type":"dc:BibliographicResource","dc:abstract":"Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the rate-limiting enzyme in the hexosamine biosynthetic pathway which yields precursors required for protein and lipid glycosylation. Mutations in GFPT1 and other genes downstream of this pathway cause congenital myasthenic syndrome (CMS) characterized by fatigable muscle weakness owing to impaired neurotransmission. The precise pathomechanisms at the neuromuscular junction (NMJ) owing to a deficiency in GFPT1 is yet to be discovered. One of the challenges we face is the viability of Gfpt1-/- knockout mice. In this study, we use Cre/LoxP technology to generate a muscle-specific GFPT1 knockout mouse model, Gfpt1tm1d/tm1d, characteristic of the human CMS phenotype. Our data suggest a critical role for muscle derived GFPT1 in the development of the NMJ, neurotransmission, skeletal muscle integrity and highlight that a deficiency in skeletal muscle alone is sufficient to cause morphological postsynaptic NMJ changes that are accompanied by presynaptic alterations despite the conservation of neuronal GFPT1 expression. In addition to the conventional morphological NMJ changes and fatigable muscle weakness, Gfpt1tm1d/tm1d mice display a progressive myopathic phenotype with the presence of tubular aggregates in muscle, characteristic of the GFPT1-CMS phenotype. We further identify an upregulation of skeletal muscle proteins glypican-1, farnesyltransferase/geranylgeranyltransferase type-1 subunit Î± and muscle-specific kinase, which are known to be involved in the differentiation and maintenance of the NMJ. The Gfpt1tm1d/tm1d model allows for further investigation of pathophysiological consequences on genes and pathways downstream of GFPT1 likely to involve misglycosylation or hypoglycosylation of NMJs and muscle targets.","dc:creator":"Issop Y","dc:date":"2018","dc:title":"GFPT1 deficiency in muscle leads to myasthenia and myopathy in mice."},"rdfs:label":"Issop 2018 Mouse"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":3,"dc:description":"The phenotype of the knockout mouse significantly recapitulates human disease."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":8739,"specifiedBy":"GeneValidityCriteria10","strengthScore":18,"subject":{"id":"cggv:58af8cbe-1819-4a68-ae30-8aeb6324bf68","type":"GeneValidityProposition","disease":"obo:MONDO_0012518","gene":"hgnc:4241","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"GFPT1 was first reported in relation to autosomal recessive congenital myasthenic syndrome 12 in 2011 (Senderek et al., PMID: 21310273). Twelve variants (missense, nonsense, frameshift, splicing) that have been reported in 8 probands in 2 publications (PMIDs: 21310273, 23794683) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts) has been reached. Congenital myasthenic syndrome 12 is characterized by limb-girdle muscle weakness and tubular aggregates on muscle biopsies. The disease mechanism appears to be biallelic loss of function. Heterozygous carriers are reportedly unaffected. This gene-disease relationship is also supported by the biochemical function of GFPT1, which is involved in the hexosamine biosynthesis pathway that serves as a source of essential amino sugars for the synthesis of glycoproteins, glycolipids, and proteoglycans, animal models that recapitulate disease, and expression in skeletal muscle (PMIDs: 21310273, 29905857, 11679416). In summary, there is definitive evidence supporting the relationship between GFPT1 and to autosomal recessive congenital myasthenic syndrome 12.This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Congenital Disorders of Glycosylation GCEP on the meeting date July 3, 2024 (SOP Version 10).","dc:isVersionOf":{"id":"cggv:a8f8af21-a5dc-41aa-9bd3-b38c3a98d55c"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}